These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 32176645

  • 1. Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls.
    Feinkohl I, Schipke CG, Kruppa J, Menne F, Winterer G, Pischon T, Peters O.
    J Alzheimers Dis; 2020; 74(4):1285-1294. PubMed ID: 32176645
    [Abstract] [Full Text] [Related]

  • 2. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ, Yi S, Han JY, Park SY, Jang JW, Chun IK, Kim SE, Lee BS, Kim GJ, Yu JS, Lim K, Kang SM, Park YH, Youn YC, An SSA, Kim S.
    Alzheimers Res Ther; 2017 Dec 15; 9(1):98. PubMed ID: 29246249
    [Abstract] [Full Text] [Related]

  • 3. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
    Shahpasand-Kroner H, Klafki HW, Bauer C, Schuchhardt J, Hüttenrauch M, Stazi M, Bouter C, Wirths O, Vogelgsang J, Wiltfang J.
    Alzheimers Res Ther; 2018 Dec 08; 10(1):121. PubMed ID: 30526652
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Multiplex immunoassay measurement of amyloid-β42 to amyloid-β40 ratio in plasma discriminates between dementia due to Alzheimer's disease and dementia not due to Alzheimer's disease.
    Vogelgsang J, Shahpasand-Kroner H, Vogelgsang R, Streit F, Vukovich R, Wiltfang J.
    Exp Brain Res; 2018 May 08; 236(5):1241-1250. PubMed ID: 29480353
    [Abstract] [Full Text] [Related]

  • 7. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.
    Chatterjee P, Elmi M, Goozee K, Shah T, Sohrabi HR, Dias CB, Pedrini S, Shen K, Asih PR, Dave P, Taddei K, Vanderstichele H, Zetterberg H, Blennow K, Martins RN.
    J Alzheimers Dis; 2019 May 08; 71(3):775-783. PubMed ID: 31424403
    [Abstract] [Full Text] [Related]

  • 8. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
    Fei M, Jianghua W, Rujuan M, Wei Z, Qian W.
    J Neurol Sci; 2011 Jun 15; 305(1-2):92-6. PubMed ID: 21440911
    [Abstract] [Full Text] [Related]

  • 9. Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention.
    Udeh-Momoh C, Zheng B, Sandebring-Matton A, Novak G, Kivipelto M, Jönsson L, Middleton L.
    J Prev Alzheimers Dis; 2022 Jun 15; 9(1):12-21. PubMed ID: 35098969
    [Abstract] [Full Text] [Related]

  • 10. Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma.
    Pérez-Grijalba V, Fandos N, Canudas J, Insua D, Casabona D, Lacosta AM, Montañés M, Pesini P, Sarasa M.
    J Alzheimers Dis; 2016 Sep 06; 54(2):751-62. PubMed ID: 27567833
    [Abstract] [Full Text] [Related]

  • 11. Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease.
    Teunissen CE, Chiu MJ, Yang CC, Yang SY, Scheltens P, Zetterberg H, Blennow K.
    J Alzheimers Dis; 2018 Sep 06; 62(4):1857-1863. PubMed ID: 29614646
    [Abstract] [Full Text] [Related]

  • 12. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
    Park JC, Han SH, Cho HJ, Byun MS, Yi D, Choe YM, Kang S, Jung ES, Won SJ, Kim EH, Kim YK, Lee DY, Mook-Jung I.
    Alzheimers Res Ther; 2017 Mar 22; 9(1):20. PubMed ID: 28330509
    [Abstract] [Full Text] [Related]

  • 13. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease.
    Giedraitis V, Sundelöf J, Irizarry MC, Gårevik N, Hyman BT, Wahlund LO, Ingelsson M, Lannfelt L.
    Neurosci Lett; 2007 Nov 12; 427(3):127-31. PubMed ID: 17936506
    [Abstract] [Full Text] [Related]

  • 14. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.
    Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM.
    Arch Neurol; 2000 Jan 12; 57(1):100-5. PubMed ID: 10634455
    [Abstract] [Full Text] [Related]

  • 15. A Sensitive and Cost-Effective Chemiluminescence ELISA for Measurement of Amyloid-β 1-42 Peptide in Human Plasma.
    Mehta PD, Patrick BA, Miller DL, Coyle PK, Wisniewski T.
    J Alzheimers Dis; 2020 Jan 12; 78(3):1237-1244. PubMed ID: 33252086
    [Abstract] [Full Text] [Related]

  • 16. Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease.
    Tzen KY, Yang SY, Chen TF, Cheng TW, Horng HE, Wen HP, Huang YY, Shiue CY, Chiu MJ.
    ACS Chem Neurosci; 2014 Sep 17; 5(9):830-6. PubMed ID: 25054847
    [Abstract] [Full Text] [Related]

  • 17. The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease.
    Wang T, Xiao S, Liu Y, Lin Z, Su N, Li X, Li G, Zhang M, Fang Y.
    Int J Geriatr Psychiatry; 2014 Jul 17; 29(7):713-9. PubMed ID: 24318929
    [Abstract] [Full Text] [Related]

  • 18. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
    Pérez-Grijalba V, Romero J, Pesini P, Sarasa L, Monleón I, San-José I, Arbizu J, Martínez-Lage P, Munuera J, Ruiz A, Tárraga L, Boada M, Sarasa M.
    J Prev Alzheimers Dis; 2019 Jul 17; 6(1):34-41. PubMed ID: 30569084
    [Abstract] [Full Text] [Related]

  • 19. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.
    Blennow K, De Meyer G, Hansson O, Minthon L, Wallin A, Zetterberg H, Lewczuk P, Vanderstichele H, Vanmechelen E, Kornhuber J, Wiltfang J, KND-Study Group, Heuser I, Maier W, Luckhaus C, Rüther E, Hüll M, Jahn H, Gertz HJ, Frölich L, Hampel H, Pernetzki R.
    J Nutr Health Aging; 2009 Mar 17; 13(3):205-8. PubMed ID: 19262954
    [Abstract] [Full Text] [Related]

  • 20. Plasma concentrations of free amyloid β cannot predict the development of Alzheimer's disease.
    Lövheim H, Elgh F, Johansson A, Zetterberg H, Blennow K, Hallmans G, Eriksson S.
    Alzheimers Dement; 2017 Jul 17; 13(7):778-782. PubMed ID: 28073031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.